Table 3.
The top 20 substances for which the most pDDIs were identified in the cohort of MS patients (N = 627).
| Active ingredient | pDDI count | Degree of pDDI severity, N | Patients, N (%) | p a | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mild | Mild-severe | Moderate | Moderate-severe | Severe | Total (N = 627) | Pw/P (N = 334) | Pw/oP (N = 293) | |||
| Methylprednisolone | 247 | 106 | 51 | 63 | 22 | 5 | 123 (19.6%) | 110 (32.9%) | 13 (4.4%) | <0.001 |
| Acetylsalicylic acid | 232 | 83 | 37 | 72 | 33 | 7 | 55 (8.8%) | 48 (14.4%) | 7 (2.4%) | <0.001 |
| Ibuprofen | 211 | 87 | 37 | 28 | 53 | 6 | 105 (16.7%) | 61 (18.3%) | 44 (15.0%) | 0.286 |
| Pantoprazole | 190 | 122 | 6 | 61 | 0 | 1 | 178 (28.4%) | 155 (46.4%) | 23 (7.8%) | <0.001 |
| Baclofen | 189 | 107 | 17 | 58 | 7 | 0 | 78 (12.4%) | 72 (21.6%) | 6 (2.0%) | <0.001 |
| Ramipril | 164 | 80 | 7 | 41 | 31 | 5 | 53 (8.5%) | 41 (12.3%) | 12 (4.1%) | <0.001 |
| Bisoprolol | 151 | 95 | 30 | 18 | 8 | 0 | 51 (8.1%) | 46 (13.8%) | 5 (1.7%) | <0.001 |
| Cannabidiol | 139 | 121 | 3 | 14 | 1 | 0 | 46 (7.3%) | 40 (12.0%) | 6 (2.0%) | <0.001 |
| Dronabinol | 136 | 120 | 5 | 6 | 5 | 0 | 47 (7.5%) | 41 (12.3%) | 6 (2.0%) | <0.001 |
| Torasemide | 127 | 60 | 10 | 54 | 3 | 0 | 22 (3.5%) | 22 (6.6%) | 0 (0.0%) | <0.001 |
| Citalopram | 122 | 36 | 32 | 11 | 16 | 27 | 33 (5.3%) | 25 (7.5%) | 8 (2.7%) | 0.011 |
| Enoxaparin | 112 | 33 | 0 | 6 | 71 | 2 | 127 (20.3%) | 114 (34.1%) | 13 (4.4%) | <0.001 |
| Hydrochlorothiazide | 94 | 42 | 5 | 39 | 6 | 2 | 8 (1.3%) | 7 (2.1%) | 1 (0.3%) | 0.073 |
| Metoprolol | 90 | 53 | 17 | 18 | 2 | 0 | 29 (4.6%) | 25 (7.5%) | 4 (1.4%) | <0.001 |
| Levothyroxine | 90 | 47 | 3 | 37 | 3 | 0 | 82 (13.1%) | 55 (16.5%) | 27 (9.2%) | 0.009 |
| Amlodipine | 86 | 40 | 18 | 25 | 3 | 0 | 25 (4.0%) | 22 (6.6%) | 3 (1.0%) | <0.001 |
| Duloxetine | 84 | 63 | 3 | 5 | 10 | 3 | 21 (3.3%) | 19 (5.7%) | 2 (0.7%) | <0.001 |
| Zopiclone | 83 | 70 | 1 | 10 | 0 | 2 | 65 (10.4%) | 58 (17.4%) | 7 (2.4%) | <0.001 |
| Magnesium | 79 | 76 | 3 | 0 | 0 | 0 | 65 (10.4%) | 49 (14.7%) | 16 (5.5%) | <0.001 |
| Calcium | 73 | 63 | 0 | 9 | 1 | 0 | 33 (5.3%) | 32 (9.6%) | 1 (0.3%) | <0.001 |
The table is sorted by the total number of pDDIs per drug in the data set (pDDI count). In addition, the number of pDDIs broken down by degree of severity and the number of MS patients who received the respective drugs are provided. MS, multiple sclerosis; N, number of patients; pDDI, potential drug–drug interaction; Pw/oP, patients without polypharmacy; Pw/P, patients with polypharmacy.
a
p: p-value according to Fisher’s exact test for comparing Pw/P and Pw/oP (significant differences are indicated in bold).